- Home
- PRTS vs SCYX Comparison
PRTS vs SCYX Comparison
Compare PRTS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTS
- SCYX
- Stock Information
- Founded
- PRTS 1995
- SCYX 1999
- Country
- PRTS United States
- SCYX United States
- Employees
- PRTS N/A
- SCYX N/A
- Industry
- PRTS Auto & Home Supply Stores
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- PRTS Consumer Discretionary
- SCYX Health Care
- Exchange
- PRTS Nasdaq
- SCYX Nasdaq
- Market Cap
- PRTS 40.0M
- SCYX 32.3M
- IPO Year
- PRTS 2007
- SCYX 2014
- Fundamental
- Price
- PRTS $0.70
- SCYX $0.79
- Analyst Decision
- PRTS Hold
- SCYX
- Analyst Count
- PRTS 1
- SCYX 0
- Target Price
- PRTS $0.70
- SCYX N/A
- AVG Volume (30 Days)
- PRTS 1.3M
- SCYX 574.3K
- Earning Date
- PRTS 10-28-2025
- SCYX 11-05-2025
- Dividend Yield
- PRTS N/A
- SCYX N/A
- EPS Growth
- PRTS N/A
- SCYX N/A
- EPS
- PRTS N/A
- SCYX N/A
- Revenue
- PRTS $577,614,000.00
- SCYX $3,257,000.00
- Revenue This Year
- PRTS N/A
- SCYX $422.61
- Revenue Next Year
- PRTS $2.62
- SCYX $240.56
- P/E Ratio
- PRTS N/A
- SCYX N/A
- Revenue Growth
- PRTS N/A
- SCYX N/A
- 52 Week Low
- PRTS $0.68
- SCYX $0.66
- 52 Week High
- PRTS $1.42
- SCYX $1.62
- Technical
- Relative Strength Index (RSI)
- PRTS 40.05
- SCYX 36.53
- Support Level
- PRTS $0.69
- SCYX $0.74
- Resistance Level
- PRTS $0.80
- SCYX $1.14
- Average True Range (ATR)
- PRTS 0.04
- SCYX 0.07
- MACD
- PRTS -0.01
- SCYX -0.04
- Stochastic Oscillator
- PRTS 8.38
- SCYX 11.22
About PRTS CarParts.com Inc.
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.